The new application, TargetSelector, streamlines
target-protein discovery and enables researchers in various
industries to identify novel targets for innovative
products
REHOVOT, Israel, July 25,
2023 /PRNewswire/ -- Evogene Ltd.
(Nasdaq: EVGN) (TASE: EVGN), a leading computational biology
company targeting to revolutionize life-science product discovery
and development across multiple market segments, is proud to
announce the latest addition to its ChemPass AI
tech-engine – a breakthrough technology for target-protein
discovery. The integration of TargetSelector, a new application
that streamlines target-protein discovery for active molecule
identification, assists researchers in finding suitable target
proteins for new products while reducing development time,
resources and most importantly, increasing the probability of
success.
Proteins play a fundamental role in a wide array of biological
processes and serve as the primary targets for developing
innovative therapeutics, ag-chemical, ag-biological, and other life
science solutions. The precise identification of these protein
targets is pivotal in advancing research and discovery across
various domains, including pharmaceuticals, agriculture, and
environmental applications.
The challenge of finding a target-protein that is novel, safe,
and druggable from the thousands of proteins in a relevant organism
is enormous. Leveraging predictive machine learning algorithms and
genomic data, users gain valuable insights into product
requirements such as homology, druggability, essentiality, and
biological pathways, efficiently narrowing down the list of
potential target-protein, thus optimizing the discovery
process.
"ChemPass AI tech-engine is a cutting-edge platform for
the identification of small molecules. The addition of the
TargetSelector application now enables a broader scope of finding
the optimal target-protein for these molecules," said Dr.
Nir Arbel, CPO at Evogene. "Our
subsidiary AgPlenus, which focuses on developing ag chemicals, will
be the first to benefit from this new improvement, applying it to
identify novel mechanisms of action for pesticides. I believe
that this significant advancement in Evogene's ChemPass AI
tech-engine, positions us to forge strategic partnerships with
industry leaders, unlocking innovation, expediting product
development, and delivering groundbreaking solutions that tackle
pressing global challenges."
About ChemPass AI:
ChemPass AI tech engine is a cutting-edge computational
platform for discovering and optimizing small molecules for various
life-science products, such as therapeutics and ag-chemicals.
Developed at the intersection of docking techniques and machine
learning, ChemPass AI brings together the power of
artificial intelligence, predictive biology, and molecular
interactions to accelerate target-protein and active molecule
discovery processes like never before.
ChemPass AI has been trained on vast repositories of
molecular data encompassing diverse chemical structures and
biological targets. This wealth of knowledge empowers the platform
to recognize intricate patterns, subtle interactions, and complex
relationships between small molecules and their target-proteins. As
a result, ChemPass AI can rapidly evaluate an organism's
protein set (proteome) as well as billions of potential candidates,
ranking them according to their likelihood of success and
shortening the time needed to identify promising target-proteins
and leads (small molecules).
About Evogene:
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational
biology company leveraging big data and artificial
intelligence, aiming to revolutionize the development of
life-science based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost.
Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI. Each tech-engine is
focused on the discovery and development of products based on one
of the following core components: microbes (MicroBoost AI),
small molecules (ChemPass AI), and genetic elements
(GeneRator AI).
Evogene uses its tech-engines to develop products through
strategic partnerships and collaborations, and its five
subsidiaries including:
- Biomica Ltd. (www.biomicamed.com) developing and
advancing novel microbiome-based therapeutics to treat human
disorders powered by MicroBoost AI;
- Lavie Bio
Ltd. (www.lavie-bio.com) - developing and
commercially advancing, microbiome based ag-biologicals powered by
MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) -developing next
generation ag chemicals for effective and sustainable crop
protection powered by ChemPass AI;
-
Canonic Ltd. (www.canonicbio.com) –
developing medical cannabis products based on decoding plant
genetics for optimized therapeutic effect powered
by GeneRator AI; and
- Casterra Ag Ltd. (www.casterra.co)–
developing and marketing superior castor seed varieties producing
high yield and high-grade oil content, on an industrial scale for
the biofuel and other industries powered by GeneRator
AI.
For more information, please visit: www.evogene.com.
Forward-Looking Statements: This press release
contains "forward-looking statements" relating to future events.
These statements may be identified by words such as "may", "could",
"expects", "hopes" "intends", "anticipates", "plans", "believes",
"scheduled", "estimates", "demonstrates" or words of similar
meaning. For example, Evogene and its subsidiaries are using
forward-looking statement in this press release when it discusses
TargetSelector's ability to assist researchers in finding suitable
target proteins for new products while reducing development time,
resources and increasing the probability of success,
TargetSelector's ability to enable a broader scope of finding the
optimal protein target for hit small molecules, AgPlenus' success
in identifying novel mechanism of action pesticides, and ChemPass
AI's ability to accelerate drug discovery processes by reducing the
time and resources required. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, those risk factors contained in
Evogene's reports filed with the applicable securities authority.
In addition, Evogene and its subsidiaries rely, and expect to
continue to rely, on third parties to conduct certain activities,
such as their field-trials and pre-clinical studies, and if these
third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected
deadlines, Evogene and its subsidiaries may experience significant
delays in the conduct of their activities. Evogene and its
subsidiaries disclaim any obligation or commitment to update these
forward-looking statements to reflect future events or developments
or changes in expectations, estimates, projections, and
assumptions.
Logo -
https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
Contact:
Rachel Pomerantz
Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
+972-8-9311901
View original
content:https://www.prnewswire.com/news-releases/evogenes-chempass-ai-tech-engine-is-introduced-with-new-breakthrough-machine-learning-technology-for-target-protein-discovery-301884822.html
SOURCE Evogene